US Patent

US7851504 — Enhanced bimatoprost ophthalmic solution

Composition of Matter · Assigned to Allergan Inc · Expires 2027-06-13 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a composition of bimatoprost, an ophthalmic solution for treating glaucoma or ocular hypertension.

USPTO Abstract

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Drugs covered by this patent

Lumigan (BIMATOPROST)

Patent Metadata

Patent number: US7851504
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-06-13
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Allergan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.